





Key findings learned through ESD; IVI experience

Dr. Alberto Tejera
Alberto.tejera@ivi.es

- ✓ Standard methods of embryo assessment:
Subjective morphology evaluation.
- ✓ Search of additional markers of viability
- ✓ More information to supplement current criteria for embryo selection




- ✓ **New embryo behavior**
- ✓ **New categories for embryo evaluation**
- ✓ **Checking the best timing to IVM**
- ✓ **New markers of implantation: exclusion and inclusion criteria**
- ✓ **New algorithm of embryo selection**
- ✓ **Validation of ESD with RCT**






✓ New embryo behavior

cc2= t3-t2 **Time-Lapse** **s2= t4-t3**




cc3= t5-t3 **s3= t8-t5**



2 types of embryo populations


$$cc2 = t3 - t2$$

5-12 h




$$cc3 = t5 - t3$$

12-16 h




$$s2 = t4 - t3$$

<0,75



$$s3 = t8 - t5$$


0-3 h







Time of compaction

70 h

tM







Early compaction

N= 3532 couples

N= 3782 embryos with KID (Known implantation data)

During Blastocyst expansion, embryo is partially or fully collapsed or contracted one or several times prior to transfer.


INCIDENCE RATE
19,1%




N= 507 cases
N= 715 blastocysts

Collapse or blastocyst contraction

With the ESD we can detect triploid zygotes that we couldn't detect with a conventional evaluation




% TPN




Detection of Triploid zygotes


- ✓ New embryo behaviors
- ✓ New categories for embryo evaluation
- ✓ Checking the best timing to IVM
- ✓ New markers of implantation: exclusion and inclusion criteria
- ✓ New algorithm of embryo selection
- ✓ Validation of ESD with RCT




It seems that the morphological classification is not very precise.



Different point of view...




Comparing implantation rates



- ✓ Only morphology criteria, is not able to select the best embryo from a cohort.
- ✓ It is important to use a combination of both classifications

- ✓ New embryo behaviors
- ✓ New categories for embryo evaluation
- ✓ **Checking the best timing to IVM**
- ✓ New markers of implantation: exclusion and inclusion criteria
- ✓ New algorithm of embryo selection
- ✓ Validation of ESD with RCT



Checking the best IVM timing

Day 1 or 2

Checking maturation



n=88



A23187
8mM
5 min

Puromycin
10µg/mL
5 hrs

Partenogenetic activation

Response
after
activation

Day 2 o 3




No activation (MI)	Incomplete Activation (IA)	Normal Activation (NA)	Abnormal Activation I (ANAI)	Abnormal Activation II (ANAI)
(1PB+0PN)	(1PB+2PB+0PN)	(1PB+2PB+1PN)	(1PB+2PB+>1PN)	(1PB+≥1PN)

Checking the best IVM timing

**Early IVM
(70.5%)**

n=62
≤22 hours

$18.4 \pm 2.7h^*$






$4.8 \pm 2.3hrs^*$

$13.1 \pm 2.7hrs$

**Late IVM
(29.5%)**

n=26
>22 hours

$26.3 \pm 3.8hrs^*$




$10.3 \pm 4.1hrs^*$

$15.7 \pm 3.0hrs$

The early IVM gives rise to higher % of normal activation compare to late IVM (61.3% vs. 34.6%)



	Activation	No activation (MII)	Incomplete Activation (IA)	Normal Activation(NA)	Abnormal Activation I (ANAI)	Abnormal Activation II (ANAI)
	(IA+NA+ANAI+ANAI)	(1PB+0PN)	(1PB+2PB+0PN)	(1PB+2PB+1PN)	(1PB+2PB+>1PN)	(1PB+≥1PN)
E-IVM (n=62)	57 (91.9%) a	5 (8.0%)	0	38 (61.3%) a	16 (25.8%) a	3 (4.8%)
L-IVM (n=26)	21 (80.8%) a	5 (19.2%)	2 (7.7%)	9 (34.6%) b	7 (26.9%) a	3 (11.5%)
Total (n=88)	78 (88.6%)	10 (11.4%)	2 (2.3%)	47 (53.4%)	23 (26.1%)	6 (6.8%)

- ✓ New embryo behavior
- ✓ New categories for embryo evaluation
- ✓ Checking the best timing to IVM
- ✓ New markers of implantation: exclusion and inclusion criteria
- ✓ New algorithm of embryo selection
- ✓ Validation of ESD with RCT





1st Exclusion criteria: Uneven blastomere size after the first cleavage

Definition: Blastomeres were considered uneven sized if the average diameter of the largest blastomere was more than 25% larger than the average diameter of the small blastomere.





2nd Exclusion criteria: Multi-nucleation at the four-cell stage

Definition: Embryos were considered MN at the 4 cell stage when more than one distinct nucleus was observed in one (or more) blastomeres.



3rd Exclusion criteria: Abrupt division from one to three cells




Definition: A cleavage from zygote to three blastomere embryo or a cleavage from zygote to two blastomeres in less than 5 hours.



Limited implantation success of direct-cleaved human zygotes: a time-lapse study





New markers of implantation: inclusion criteria





Predictive ability of embryo implantation


Best correlation with implantation success




cc2= t3-t2






t5





- ✓ New embryo behaviors
- ✓ New categories for embryo evaluation
- ✓ Checking the best timing to IVM
- ✓ New markers of implantation: exclusion and inclusion criteria
- ✓ New algorithm of embryo selection
- ✓ Validation of ESD with RCT







**Based on a
Logistic Regression model**




tEB




t5-t2



% Implantation according to the category






S3=t8-t5





Morphokinetic algorithm based on parameters on day 3 and Genetic content


N= 504 embryos



Increasing the probability of selecting chromosomally normal embryos by time-lapse morphokinetics analysis

Natalia Basile, Ph.D.,^a Maria Del Carmen Nogales, Ph.D.,^a Fernando Bronet, Ph.D.,^a Mireia Florensa, Ph.D.,^b Marissa Riquero, Ph.D.,^b Lorena Rodrigo, Ph.D.,^c Juan García-Velasco, M.D.,^a and Marcos Meseguer, Ph.D.^d
^aIVI Madrid, Madrid; ^bIVI Barcelona, Barcelona; ^cIVIOMICS, Valencia; and ^dInstituto Valenciano de Infertilidad, Universidad de Valencia, Valencia, Spain


- ✓ **New embryo behaviors**
- ✓ **New categories for embryo evaluation**
- ✓ **Checking the best timing to IVM**
- ✓ **New markers of implantation: exclusion and inclusion criteria**
- ✓ **New algorithm of embryo selection**
- ✓ **Validation of ESD with RCT**



Embryo incubation and selection in a time-lapse monitoring system improves pregnancy outcome compared with a standard incubator: a retrospective cohort study

Marcos Meseguer, Ph.D.,^a Irene Rubio, Ph.D.,^a Maria Cruz, Ph.D.,^b Natalia Basile, Ph.D.,^c Julian Marcos, Ph.D.,^d and Antonio Requena, M.D.^c

^a IVI, Universidad de Valencia, Valencia; ^b IVI Alicante, Alicante; ^c IVI Madrid, Madrid; and ^d IVI Murcia, Murcia, Spain



Prospective Study:

Controlled study where patients are randomly distributed between both groups.

Retrospective Study:


Where patients are distributed between both groups before the study has been designed.

Limitation:

- ✓ Patients may not be evenly distributed between the 2 different incubators which can affect final conclusions.

Analyse for possible confounding factors:


- ✓ Significantly influence pregnancy rates
- ✓ Uneven distribution between incubators.



- ✓ Type of incubator
- ✓ Own treatment/oocyte donation
- ✓ Transfer day
- ✓ Oocyte origin
- ✓ N° of MII

- ✓ Patient age
- ✓ N° of previous treatments
- ✓ N° of embryos transferred
- ✓ IMCI
- ✓ Clinic

Type of treatment: autologous or donation



Conventional incubator



Disadvantage

TMS Incubator



Advantage


- ✓ Uneven distribution
- ✓ This factor gives advantage to TMS (and higher pregnancy rates than CI)

Estimated Improvement of ESD


Transfer day:

Conventional incubator

TMS Incubator




Advantage



Disadvantage

Disadvantage of TMS vs conventional incubator

Estimated Improvement of ESD




Odds Ratio for clinical pregnancy based on 7305 cycles with oocyte retrieval

Factor	Comparison	Crude Estimate	Logistic Regression model			
			Estimate	Lower CL	Upper CL	P-value
Incubation	TMS versus SI	1,190	1,201	1,059	1,363	0,0043
Day of Transfer	Day 5 versus Day 3	1,272	1,169	1,039	1,312	0,0092
Donation cycle	Donation versus Autologous	1,786	1,921	1,674	2,205	0,0000
Per year of Age	Per year less in Autocycles	1,057	1,100	1,080	1,121	0,0000
	Per year less in Donation cycles	0,971	1,019	1,003	1,035	0,0194
Number of oocytes	Peer oocyte less in Autologues cycles	0,951	0,974	0,959	0,989	0,0005
	Per oocyte less in Donation cycles	0,914	0,946	0,925	0,966	0,0000


- Effect of ESD on clinical pregnancy;

OR= 1.201 (CI95% 1.059-1.363) p=0.0043

SI → ESD



- ✓ **New embryo behaviors**
- ✓ **New categories for embryo evaluation**
- ✓ **Checking the best timing to IVM**
- ✓ **New markers of implantation: exclusion and inclusion criteria**
- ✓ **New algorithm of embryo selection**
- ✓ **Validation of ESD with RCT**



Randomized Control Trial

ARTICLE IN PRESS

ORIGINAL ARTICLE: ASSISTED REPRODUCTION

Clinical validation of embryo culture and selection by morphokinetic analysis: a randomized, controlled trial of the EmbryoScope

Irene Rubio, Ph.D.,^a Arancha Galán, Ph.D.,^a Zaloa Larreategui, Ph.D.,^b Fernando Ayerdi, Ph.D.,^b
Jose Bellver, M.D.,^a Javier Herrero, Ph.D.,^a and Marcos Meseguer, Ph.D.^a

^a Instituto Universitario IVI Valencia, University of Valencia, Valencia; and ^b IVI Bilbao, Bilbao, Spain

Randomized Control Trial

TABLE 1

Descriptive characteristics of the patient and IVF laboratory practice in the time-lapse and control groups.

	TMS group (n = 438)	Control group (n = 405)	P value
Age (y), patients and recipients	34.7 ± 2.7 (34.4–34.9)	34.6 ± 2.7 (34.4–34.9)	NS
Age (y), patients and donors	30.4 ± 5.5 (29.9–31.0)	30.0 ± 5.5 (29.5–30.5)	NS
BMI (kg/m ²)	23.2 ± 3.7 (22.6–23.7)	23.04 ± 2.8 (22.5–23.5)	NS
COS protocol			
Long GnRH agonist (%)	14.8 (65)	16.4 (66)	NS
Short GnRH antagonist (%)	85.2 (373)	83.6 (339)	NS
Total dose of FSH	1,781 ± 631 (1,709–1,853)	1,832 ± 603 (1,763–1,900)	NS
Total dose of hMG	1,127 ± 664 (1,035–1,219)	990 ± 538 (913–1,066)	NS
E ₂ on hCG day (pg/mL)	1,981 ± 943 (1,882–2,079)	1,964 ± 962 (1,860–2,067)	NS
P ₄ on hCG day (ng/mL)	0.76 ± 0.38 (0.72–0.80)	0.74 ± 0.35 (0.70–0.78)	NS
Days of stimulation	13.0 ± 3.45 (12.5–13.6)	13.2 ± 3.42 (12.6–13.8)	NS
Donor recipients (%)	47.8 (208) (43.2–52.6)	49.1 (200) (44.2–53.9)	NS
Metaphase II oocytes (n)	8.0 ± 2.7 (7.76–8.26)	8.1 ± 3.0 (7.8–8.3)	NS
Fertilization rate (%)	75.3 ± 16.5 (73.8–76.9)	74.0 ± 17.4 (72.3–75.7)	NS
Day 3 ET (% of total)	72.5 % (318) (68.3–76.7)	75.5 % (306) (71.3–79.7)	NS
Blastocyst ET (%)	27.5 (120) (23.3–31.7)	24.5 (99) (20.3–28.7)	

Note: Values are mean, and values in brackets are 95% confidence intervals or the total number of patients. BMI = body mass index; COS = controlled ovarian stimulation; E₂ = estradiol; ET = embryo transfer; FSH = follicle-stimulating hormone; GnRH = gonadotropin-releasing hormone; hCG = human chorionic gonadotropin; hMG = human menopausal gonadotropin; NS = not statistically significant; P₄ = progesterone; TMS = time-lapse monitoring system.




TABLE 2

Descriptive characteristics of the embryo development and fate in the time-lapse and control groups.

	TMS group (n = 2,638)	Control group (n = 2,427)	P value
Embryo fragmentation (%)	7.5 ± 0.1 (7.2–7.9)	6.9 ± 9.4 (6.5–7.1)	.006
No. of blastomeres	6.9 ± 2.3 (6.8–6.9)	6.9 ± 2.7 (6.8–7.0)	NS
Embryo symmetry	1.7 ± 0.5 (1.7–1.7)	1.7 ± 0.5 (1.7–1.7)	NS
Optimal embryos (day 3) (%)	46.2 (1,219) (44.3–48.1)	43.1 (1,046) (41.3–45.1)	.010
Blastocyst rate (%)	52.3 (576) (50.3–54.2)	50.5 (471) (48.5–52.5)	NS
Optimal blastocyst (day 5) (%)	20.9 (230) (19.4–22.4)	16.6 (155) (15.1–18.1)	.001
Transferred embryos	1.86 ± 0.37 (1.8–1.9)	1.86 ± 0.40 (1.8–1.9)	NS
Cryopreserved embryos	3.9 ± 2.2 (3.6–4.1)	3.6 ± 2.2 (3.4–3.9)	NS

Note: Values are mean, and values in brackets are 95% confidence interval or the total number of embryos.

Rubio. Clinical validation of EmbryoScope. Fertil Steril 2014.



TABLE 3

Outcome results per intention to treat, per cycle, per transfers and per embryo transferred.

Outcome	TMS group	Control group	RR	P value
All cycles with oocyte retrieval	438	405		
Pregnancy (% of all treated cycles)	61.6 (56.9–66.0)	56.3 (51.4–61.0)	1.09 (0.98–1.23)	.12
Ongoing pregnancy (% of all treated cycles)	51.4 (46.7–56.0)	41.7 (37.0–46.6)	1.23 (1.06–1.43)	.005
All transfers	415	373		
Pregnancy (% of all transfers)	65.3 (60.6–69.7)	61.1 (56.1–65.9)	1.07 (0.95–1.19)	.22
Ongoing pregnancy (% of all transfers)	54.5 (49.6–59.2)	45.3 (40.3–50.4)	1.20 (1.04–1.39)	.01
All pregnant cycles	271	228		
Early pregnancy loss (% of all pregnancies)	16.6 (12.6–21.4)	25.8 (20.6–31.9)	0.64 (0.45–0.91)	.01
All transferred embryos	775	699		
Implantation rate (% of all transferred embryos)	44.9 (41.4–48.4)	37.1 (33.6–40.7)	1.43 (1.05–1.39)	.02

Note: Results shown as proportion with 95% confidence limits in brackets, relative risk (RR) with 95% confidence limits in brackets and the corresponding P value (Fisher's exact test). Total number of cycles are also presented in brackets.

Rubio. Clinical validation of EmbryoScope. Fertil Steril 2014.




TABLE 4

Logistic regression analysis of ongoing pregnancy after week 12 as affected by incubation type, day of transfer, oocyte source, and age of the patient.

Model effect	Values	OR (95% CI)	P value
Incubation	TMS versus SI	1.41 (1.06–1.86)	.015
Day of transfer	Day 5 versus day 3	1.53 (1.08–2.16)	.016
Oocyte source	Autologous versus donation	0.89 (0.60–1.30)	NS
Age	Years	Per year, 1.01 (0.98–1.05)	NS

Note: CI = confidence interval; OR = odds ratio; NS = not statistically significant; SI = standard incubator; TMS = time-lapse monitoring system.

Rubio. Clinical validation of EmbryoScope. Fertil Steril 2014.



Embryo category	N total [#]513	N implanted [#]	Implantation [%]	Embryo category	Implantation [%]
A+	122	74	60.6	A	52.9
A-	80	33	41.2		
B+	46	24	52.2	B	43.9
B-	36	12	33.3		
C+	67	30	44.8	C	39.5
C-	52	17	32.7		
D+	28	13	46.5	D	29.3
D-	30	4	13.3		
E	51	7	13.7	E	13.7

ARTICLE IN PRESS

ORIGINAL ARTICLE: ASSISTED REPRODUCTION

Clinical validation of embryo culture and selection by morphokinetic analysis: a randomized, controlled trial of the EmbryoScope

José Rubio, Ph.D.,¹ Arancha Galán, Ph.D.,² Zaira Larreategui, Ph.D.,³ Fernando Ayerdi, Ph.D.,⁴ José Beltrán, M.D.,⁵ Javier Herrero, Ph.D.,⁶ and Marcos Meseguer, Ph.D.⁷



¹ Instituto Universitario IVI Valencia, University of Valencia, Valencia; and ² IVI Bilbao, Bilbao, Spain

Hypothesis

*More Observations
Better Selection*



*Less Disturbance
Better Development*



- ✓ Morphokinetics are related with morphology but it is necessary to combine **both** of them for embryo selection
- ✓ Embryo time-lapse analysis makes it possible to identify the best moment of IVM.
- ✓ Time-lapse provides new markers of implantation with rigor and objectivity: exclusion and inclusion criteria
- ✓ Algorithm for embryo selection has been established, but the variables could change, so, each lab should develop its own algorithm
- ✓ Kinetics are related with chromosome content
- ✓ The clinical use of time-lapse for embryo selection is able to improve reproductive outcome.